Spots Global Cancer Trial Database for Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)
Official Title: Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma
Study ID: NCT01170104
Conditions
Study Description
Brief Summary: To evaluate the time to progression of the combination therapy of Transcatheter Arterial Chemoembolization (TACE) and sorafenib in patients with previously untreated advanced or metastatic hepatocellular carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Chung-Ang University Hospital, Dongjak, Seoul, Korea, Republic of
Contact Details
Name: Joung-Soon Jang, M.D.
Affiliation: Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
